Dr. Daniel E. Spratt, MD

Dr. Spratt practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Spratt's NPI, 1780905901, was assigned on June 22, 2010. Dr. Spratt graduated from Vanderbilt University School of Medicine in 2010. Dr. Spratt holds Ohio license 35.141981.

Dr. Spratt's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Spratt's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Spratt to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spratt practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Spratt's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Spratt's licenses on file in 3 states: Ohio, Michigan and South Carolina.

CMS data shows 623 Medicare services from Dr. Spratt across 12 procedure codes in 2024, for 148 Medicare patients. Medicare paid $45,191 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 148 Medicare patients who saw Dr. Spratt in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have cancer, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spratt's median patient age at 72, with 23% women.

In 2023, Dr. Spratt wrote 16 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $258 in total drug cost. In 2022, CMS named 23 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Spratt for performance year 2024, reported as part of a group. Dr. Spratt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spratt as offering telehealth.

Dmand AI links 155 papers to Dr. Spratt, published from 2019 to 2025. 2021 was the busiest year, with 38. The most frequent topics are Prostatic Neoplasms, Androgen Antagonists and Prostate-Specific Antigen. Dr. Spratt has published most often in Int J Radiat Oncol Biol Phys. Dr. Spratt's most frequent co-authors are Robert Timothy Dess, MD, Howard M. Sandler, MD and Jason A. Efstathiou, MD.

CMS Open Payments shows 106 general payments to Dr. Spratt from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 59% of the total. AstraZeneca Pharmaceuticals LP paid the most, $15,065. It also lists 1 research payment totaling $3,200 in 2023.

Dr. Spratt graduated from Vanderbilt University School of Medicine in 2010.